SecBot SecBot

TSHA

Taysha Gene Therapies, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001806310 Biotech & Drug Discovery
$4.06 −0.04 (−0.98%)
Nov 16 4:00 PM ET · prev $4.10
Market cap
$1.4B
Small cap
Consensus
Buy
95% Buy or better · 19 analysts
Median target
$12.00
+196% · range $9.00–19.00
1 year
−1.5%
from $4.12 · Nov 17
30 days
+3.0%
from $3.94
52-week range
$3.51–6.98
−42% from high · low Oct 14
Avg volume 20D
3.34M
Oct 20 spike 10.93M
Short interest
53.48M
≈16.4% of shares · +4.3%
Days to cover
14.8
at average volume
Insider net
−$2.1M
0 buyers · 2 sellers · 12 mo
New fund stakes
1
Q3 2026 13F · 1 exit
Filing reports
9
analyzed by SecBot
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $2.1M.

  • InstitutionsBULLISH

    Q3 2026: 27 added (1 new), 11 trimmed or exited. Largest new: Capitolis Liquid Global Markets $11.2M.

  • AnalystsBULLISH

    18 of 19 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +4.3% to 53.48M shares. 14.8 days to cover, ≈16.4% of shares.

  • TrendRANGE

    9% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 5.

Who's buying

13F· Q3 2026
1
new positions
1
exit
$11.2M
in new stakes
FundMoveSharesValue
Aberdeen Group plcADD3,749,140$18.3M
CAPITOLIS LIQUID GLOBAL MARKETS LLCNEW2,300,000$11.2M
FIRST TRUST ADVISORS LPADD1,169,158$5.7M
Qube Research & Technologies LtdDOUBLED901,863$4.4M
Nuveen, LLCADD695,412$3.4M
DIMENSIONAL FUND ADVISORS LPADD677,357$3.3M
VICTORY CAPITAL MANAGEMENT INCDOUBLED537,632$2.6M
ALPS ADVISORS INCADD431,669$2.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

19 analysts
Buy 95% rate it Buy or better
Strong Buy7Buy11Hold1Sell0Strong Sell0
12-month targets · 13 analysts

Price is below the lowest target. Median implies +196%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Sep 17, 2026Wolfe Research
INITIATE
INITIATEOutperform
Jul 21, 2026Goldman Sachs
MAINTAIN
MAINTAINBuy
Jul 2, 2026Citizens
REITERATE
REITERATEMarket Outperform
Jun 30, 2026Needham
MAINTAIN
MAINTAINBuy
Jun 30, 2026Baird
MAINTAIN
MAINTAINOutperform
Jun 23, 2026BMO Capital
MAINTAIN
MAINTAINOutperform

Washington

Corporate Lobbying

5 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
bought · 0 insiders
$2.1M
sold · 2 insiders
DateInsiderTypeValue
Jul 10, 2026
Nagendran Sukumar
President and Head of R&D
Jul 10, 2026
SELL$1.2M
Jun 1, 2026
Long Alison S
Director
Jun 1, 2026
AWARD21,335 sh
Jun 1, 2026
Stalfort John A III
Director
Jun 1, 2026
AWARD21,335 sh
Jun 1, 2026
Long Alison S
Director
Jun 1, 2026
AWARD42,671 sh
Jun 1, 2026
Donenberg Phillip B.
Director
Jun 1, 2026
AWARD21,335 sh
Jun 1, 2026
Donenberg Phillip B.
Director
Jun 1, 2026
AWARD42,671 sh
Jun 1, 2026
Sepp-Lorenzino Laura
Director
Jun 1, 2026
AWARD42,671 sh
Jun 1, 2026
Stalfort John A III
Director
Jun 1, 2026
AWARD42,671 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Reddit
Recent posts
All social signals and their track records

Short side

FINRA· Oct 30, 2026
53,478,497
shares short
+4.3%
vs prior settlement
14.8
days to cover
≈16.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 12, 2026 SEC
Taysha Gene Therapies reported a Q3 2026 net loss of $0.10 per share, narrower than the consensus estimate of a $0.13…
PRESS-RELEASE · Impact 5/10
Nov 12, 2026 Earnings
Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report top
Sep 30, 2026 Inst.
Aberdeen Group plc · ADD
3,749,140 shares ($18.3M)
Sep 30, 2026 Inst.
CAPITOLIS LIQUID GLOBAL MARKETS · NEW
2,300,000 shares ($11.2M)
Aug 11, 2026 SEC
Taysha Gene Therapies reported Q2 2026 EPS of -$0.13, missing consensus of -$0.11 by 18.2%, with zero revenue vs…
PRESS-RELEASE · Impact 5/10
Jul 10, 2026 Insider
Nagendran Sukumar sold 200,000 shares
President and Head of R&D @ $6.24 ($1.2M)
Jun 25, 2026 SEC
Taysha Gene Therapies is raising approximately $187.4 million ($215.6 million if underwriters' option is exercised)…
424B5 · Impact 6/10
Jun 24, 2026 Press
Taysha Gene Therapies announced the pricing of a $200M underwritten public offering of 32.5M shares at $6.00/share…
Impact 7/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 12, 2026
Earnings
Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA…
Nov 12, 2026
Earnings result
TSHA Q3 2026 Earnings: EPS $-0.1 (+24.6% vs est)
Nov 6, 2026
Press release
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company…
Oct 2, 2026
Press release
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company…
Sep 4, 2026
Press release
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology…

SecBot reports

9 filings · 4 press releases · 0 bullish · 1 bearish · 2 mixed · 6 neutral
All TSHA filing & press-release reports (13)